Qiagen Showcases Next-Generation Sequencing Solutions for Precision Medicine
Qiagen’s partnership with artificial intelligence genomics company Freenome seeks to accelerate NGS tests and advance precision medicine for cancer treatment.
Read MorePosted by Steve Halasey | Jul 2, 2018 | Research |
Qiagen’s partnership with artificial intelligence genomics company Freenome seeks to accelerate NGS tests and advance precision medicine for cancer treatment.
Read MorePosted by Steve Halasey | Jul 2, 2018 | Research |
For women who test negative for hereditary breast cancer mutations, the RiskScore test predicts 5-year and lifetime risk of breast cancer.
Read MorePosted by Steve Halasey | Jul 2, 2018 | Research |
Study finds improvements in remission, response, and symptoms for patients with major depression whose medication selection was guided by GeneSight testing.
Read MorePosted by Steve Halasey | Jun 26, 2018 | Software |
The acquisition creates a premier women’s health business unit in the high-growth genetic testing market.
Read MorePosted by Steve Halasey | Jun 19, 2018 | Research |
Compared to treatment as usual, study data showed that patients whose treatment was guided by psychotropic genetic testing experienced a 50% improvement in remission and a 30% improvement in response to treatment.
Read More